{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:14Z","timestamp":1792788494673,"version":"4.5.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Celgene (US)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0193236","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T13:26:27Z","timestamp":1522675587000},"page":"e0193236","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus"],"prefix":"10.1371","volume":"13","author":[{"given":"Kristen R.","family":"Taylor Meadows","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos W.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Opiteck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Peach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"issue":"2","key":"ref1","first-page":"817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Q Gong","year":"2005"},{"key":"ref2","first-page":"1","article-title":"B lymphocytes: development, tolerance, and their role in autoimmunity\u2013focus on systemic lupus erythematosus","author":"GJ Tob\u00f3n","year":"2013"},{"key":"ref3","first-page":"207","article-title":"Abnormalities of T cell signaling in systemic lupus erythematosus","volume":"13","author":"VR Moulton","year":"2011"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00541370","article-title":"Aberrant lymphocyte trafficking in murine systemic lupus erythematosus","volume":"6","author":"L Schrieber","year":"1986","journal-title":"Rheumatol Int"},{"issue":"15","key":"ref5","first-page":"15396","article-title":"Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration","volume":"279","author":"ML Allende","year":"2004"},{"key":"ref6","first-page":"8606878","article-title":"Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential","volume":"2016","author":"M Aoki","year":"2016"},{"key":"ref7","first-page":"77","article-title":"Role of C-C chemokine receptor type 7 and its ligands during neuroinflammation","volume":"9","author":"S Noor","year":"2012"},{"issue":"1","key":"ref8","first-page":"122","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress","volume":"28","author":"THM Pham","year":"2008"},{"issue":"6972","key":"ref9","first-page":"355","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"M Matloubian","year":"2004"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"FL Scott","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"5","key":"ref11","first-page":"1173","article-title":"FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system","volume":"158","author":"V Brinkmann","year":"2009"},{"issue":"4","key":"ref12","first-page":"373","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"JA Cohen","year":"2016"},{"issue":"2","key":"ref13","first-page":"130","article-title":"Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence","volume":"9","author":"BO Khatri","year":"2016"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","article-title":"Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study","volume":"73","author":"L Kappos","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"WJ Sandborn","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"ref16","first-page":"92","article-title":"Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection","volume":"435","author":"MBA Oldstone","year":"2013"},{"key":"ref17","first-page":"109","article-title":"S1P signaling: new therapies and opportunities","volume":"6","author":"PJ Gonzalez-Cabrera","year":"2014"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0961203306073136","article-title":"New immunosuppresor strategies in the treatment of murine lupus nephritis","volume":"16","author":"G Alperovich","year":"2007","journal-title":"Lupus"},{"key":"ref19","first-page":"804","article-title":"FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice","volume":"394","author":"S Ando","year":"2010"},{"issue":"4","key":"ref20","first-page":"707","article-title":"Effects of FTY720 in MRL-lpr\/lpr mice: therapeutic potential in systemic lupus erythematosus","volume":"29","author":"H Okazaki","year":"2002"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1073\/pnas.1525356113","article-title":"S1P1-mediated IFNAR1 degradation modulated plasmacytoid dendritic cell interferon-\u03b1 autoamplification","volume":"113","author":"JR Teijaro","year":"2016","journal-title":"P Natl Acad Sci USA"},{"issue":"14","key":"ref22","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1073\/pnas.1700878114","article-title":"Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-\u03b1 signaling","volume":"114","author":"BS Marro","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"ref23","first-page":"486","article-title":"Ligand-binding pocket shape differences between S1P<sub>1<\/sub> and S1P<sub>3<\/sub> determine efficiency of chemical probe identification by uHTS","volume":"3","author":"SC Sch\u00fcrer","year":"2008"},{"issue":"6","key":"ref24","first-page":"1","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"C Kilkenny","year":"2010"},{"issue":"1","key":"ref25","first-page":"67","article-title":"The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases","volume":"18","author":"ER Hurd","year":"1975"},{"key":"ref26","first-page":"271694","article-title":"Murine models of systemic lupus erythematosus","volume":"2011","author":"D Perry","year":"2011"},{"issue":"9","key":"ref27","first-page":"1357","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"M Lech","year":"2013"},{"issue":"6","key":"ref28","first-page":"297","article-title":"Tertiary lymphoid organs in infection and autoimmunity","volume":"33","author":"K Neyt","year":"2012"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis","volume":"186","author":"A Chang","year":"2011","journal-title":"J Immunol"},{"key":"ref30","first-page":"430","article-title":"Ectopic lymphoid structures: powerhouse of autimmunity","volume":"7","author":"E Corsiero","year":"2016"},{"issue":"1","key":"ref31","first-page":"11","article-title":"Belimumab in systemic lupus erythematosus: an update for clinicians","volume":"3","author":"SS Kim","year":"2012"},{"key":"ref32","first-page":"7359","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"MR Smith","year":"2003"},{"key":"ref33","first-page":"77","article-title":"How does B cell depletion therapy work, and how can it be improved?","volume":"64","author":"EA Clark","year":"2005"},{"key":"ref34","first-page":"369","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"A Sistigu","year":"2011"},{"issue":"3","key":"ref35","first-page":"e28","article-title":"Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS","volume":"1","author":"M Mehling","year":"2014"},{"key":"ref36","first-page":"e79","article-title":"Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway","volume":"5","author":"S Oon","year":"2016"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0193236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T02:25:31Z","timestamp":1540261531000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0193236"}},"subtitle":[],"editor":[{"given":"Jose C.","family":"Crispin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0193236","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,2]]}}}